CureVac (NASDAQ:CVAC - Get Free Report) shares gapped down prior to trading on Wednesday . The stock had previously closed at $4.68, but opened at $4.36. CureVac shares last traded at $3.97, with a volume of 913,131 shares.
Analyst Upgrades and Downgrades
Separately, JMP Securities restated a "market outperform" rating and set a $16.00 target price on shares of CureVac in a report on Monday, September 16th.
View Our Latest Stock Report on CureVac
CureVac Stock Down 9.6 %
The firm has a market cap of $947.01 million, a PE ratio of 7.69, a PEG ratio of 0.24 and a beta of 2.50. The company has a debt-to-equity ratio of 0.05, a quick ratio of 6.19 and a current ratio of 6.20. The company's 50-day simple moving average is $3.00 and its two-hundred day simple moving average is $3.13.
Hedge Funds Weigh In On CureVac
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Private Advisor Group LLC bought a new position in shares of CureVac in the 3rd quarter worth approximately $30,000. International Assets Investment Management LLC purchased a new stake in CureVac in the third quarter worth $35,000. Integrated Wealth Concepts LLC bought a new position in CureVac in the third quarter worth $35,000. Bank of New York Mellon Corp purchased a new position in CureVac during the second quarter valued at $54,000. Finally, Barclays PLC bought a new stake in shares of CureVac during the 3rd quarter valued at $67,000. Institutional investors own 17.26% of the company's stock.
CureVac Company Profile
(
Get Free Report)
CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.
Further Reading
Before you consider CureVac, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CureVac wasn't on the list.
While CureVac currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
